HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ICT 2552

a vascular disrupting agent and antineoplastic agent; structure in first source

Also Known As:

ICT-2552; ICT2552

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - ICT 2552: 2
Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - Thiourea: 362
      - ICT 2552: 2
- Sulfur Compounds: 278
  - Thiourea: 362
    - ICT 2552: 2

Experts

1.	Falconer, Robert A: 2 articles (01/2016 - 09/2010)
2.	Patterson, Laurence H: 2 articles (01/2016 - 09/2010)
3.	Shnyder, Steven D: 2 articles (01/2016 - 09/2010)
4.	Connah, David: 1 article (01/2016)
5.	Cooper, Patricia A: 1 article (01/2016)
6.	Hussain, Nosheen: 1 article (01/2016)
7.	Ugail, Hassan: 1 article (01/2016)
8.	Atkinson, Jennifer M: 1 article (09/2010)
9.	Bibby, Michael C: 1 article (09/2010)
10.	Edwards, Dylan R: 1 article (09/2010)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2010 - "Preferential hydrolysis of ICT2588 to its active metabolite (ICT2552) was observed in tumor homogenates of HT1080 relative to MCF7 homogenates, mouse plasma, and liver homogenate. "
2.	Lung Neoplasms (Lung Cancer) 01/01/2016 - "Mice bearing subcutaneously implanted H460 lung cancer xenografts were treated with a novel vascular disrupting agent, ICT-2552, and the cytotoxin doxorubicin. "

Related Drugs and Biologics

1.	Doxorubicin (Adriamycin)
2.	Cytotoxins (Cytolysins)
3.	ICT2588